Open Access

In vitro maturation of immature oocytes for fertility preservation in cancer patients compared to control patients with fertility problems in an in vitro fertilization program

Irma Virant-Klun
Irma Virant-Klun
, 
Jure Bedenk
Jure Bedenk
 and 
Nina Jancar
Nina Jancar
   | Dec 22, 2021
Radiology and Oncology's Cover Image
About this article
Previous Article
Next Article
Cite
Article Category: Research Article
Published Online: Dec 22, 2021
Page range: 119 - 128
Received: Aug 05, 2021
Accepted: Nov 25, 2021
DOI: https://doi.org/10.2478/raon-2021-0053
© 2022 Irma Virant-Klun, Jure Bedenk, Nina Jancar, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Figure 1

Types of disease in cancer patients included in this study. Breast cancer patients predominated.
Types of disease in cancer patients included in this study. Breast cancer patients predominated.

Figure 2

In vitro maturation of the oocyte in the maturation medium and in coculture with the cumulus cells of mature oocytes in the same patient at magnification 40 X (A) and magnification 100 X (B). CC = cumulus (granulosa) cells; O = oocyte; Red bar = A) 100 μm in B) 50 μm
In vitro maturation of the oocyte in the maturation medium and in coculture with the cumulus cells of mature oocytes in the same patient at magnification 40 X (A) and magnification 100 X (B). CC = cumulus (granulosa) cells; O = oocyte; Red bar = A) 100 μm in B) 50 μm

Non-significant differences in fertilized oocytes, non-cleaved zygotes, and cleavage embryos obtained by intracytoplasmic sperm injection (ICSI) on in vitro matured and in vivo matured oocytes of patients with fertility problems (in the same cycles)

ICSI cycles (n = 17) In vitro matured oocytes In vivo matured oocytes*
Number of microinjected oocytes 49 121
Fertilized oocytes (55.127 %) (57.069 %)
Non-cleaved zygotes (15.04 %) (11.68 %)
Cleavage embryos (85.223 %) (88.461 %)

Numbers and percentages of oocytes that matured in vitro in patients with different cancers compared to patients with fertility problems

Number of oocytes that underwent in vitro maturation Number of oocytes that matured in vitro
All cancer patients (n = 18) 38 / 45 25 (1.39 ± 1.04 per patient)* (66.0%)
Patients with breast cancer (n = 8) 22 12 (54.5%)
Patients with other cancers (n = 10) 16 13 (81.2%)
Patients with fertility problems (n = 21) 65 / 74 52 (2.48 ± 1.83 per patient)* (80.0%)

Differences in the number, quality and immaturity of oocytes after controlled hormonal stimulation of the ovaries in cancer patients compared to patients with fertility problems

Cancer patients (n = 18) Patients with fertility problems (n = 21)
Age (years) 30.3 ± 6.3 33.4 ± 5.0
Number of retrieved oocytes 198 259
Oocytes per patient 11.0 ± 9.0 12.3 ± 9.2
Number of degenerated oocytes 17 (8.6%) 17 (6.5%)
Number of immature (MI + GV) oocytes 59 (30.0%)* 113 (43.6%) *
Number of immature GV oocytes 45 (23.0%) 74 (28.6%)

Non-significant differences in results of intracytoplasmic sperm injection (ICSI) cycles (fertilized oocytes, non-cleaved zygotes, cleavage embryos) on in vitro matured oocytes of patients with fertility problems regarding the number of immature (germinal vesicle [GV]) oocytes

ICSI cycles (n = 17) ≤ 30% GV oocytes ≥ 31% GV oocytes
Female age (years) 34.4 ± 3.0 34.3 ± 5.6
Number of microinjected oocytes 16 33
Fertilized oocytes 11 (69.0%) 16 (48.5%)
Non-cleaved zygotes 0 (0%) 4 (25.0%)
Cleavage embryos 11 (100%) 12 (75%)
eISSN:
1581-3207
Language:
English
Publication timeframe:
4 times per year
Journal Subjects:
Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology, Radiology
Journal RSS Feed